Biomarkers in Breast Carcinoma

Richard S.P. Huang, et al., The Oncologist

This article reports the current landscape of biomarkers in breast cancer, focusing on patients using comprehensive genomic profiling and PD‐L1 immunohistochemistry in addition to the previous standard of care diagnostics for hormone receptor and human epidermal receptor 2 identification. The relationship between different immunotherapy biomarkers in patients with triple‐negative breast cancer is examined.



Dr. Don DizonDiscussions with Don S. Dizon

Don S. Dizon is Professor of Medicine at Brown University, the Director of the Breast and Pelvic Malignancies Program and Hematology-Oncology Outpatient Clinics at Lifespan Cancer Institute, Director of Medical Oncology and the Oncology Sexual Health First Responders Clinic at Rhode Island Hospital.


In this month's blog post, Don Dizon and Meeyoung Lee discuss the importance of balancing hope with expectations when discussing Phase I trials with patients.
In this month's blog post, Don Dizon and Susannah Koontz discuss the evolution in her career as a pediatric clinical pharmacy specialist, the passions that initially drew her to the work, and that now drive her new role as a consultant.
COVID-19 has changed the way patients experience cancer care. Don Dizon and Anne Marie Mercurio discuss the impact of the pandemic on patients and their families.